High titer autoantibodies to GM-CSF in patients with AML, CML and MDS are associated with active disease

Leukemia

Volumn 22, Issue 4, 2008, Pages 783-790

  Sergeeva, A ^a   Ono, Y ^a   Rios, R ^a   Molldrem, J J ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; FREUND ADJUVANT; IMMUNOGLOBULIN A ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN M ANTIBODY; MONOCLONAL ANTIBODY PR1; PEPTIDE VACCINE; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR;

ACUTE GRANULOCYTIC LEUKEMIA; ANTIBODY TITER; ARTICLE; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; DISEASE ACTIVITY; HUMAN; HUMAN CELL; LYMPHATIC LEUKEMIA; MAJOR CLINICAL STUDY; MYELODYSPLASTIC SYNDROME; PRIORITY JOURNAL; REMISSION; SINGLE DRUG DOSE; VACCINATION;

EID: 42349114730     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/sj.leu.2405104     Document Type: Article

References (43)

1. Gasson JC. Molecular physiology of granulocyte-macrophage colony-stimulating factor. Blood 1991; 77: 1131-1145.
2. Young DC, Griffin JD. Autocrine secretion of GM-CSF in acute myeloblastic leukemia. Blood 1986; 68: 1178-1181.
3. Weisbart RH, Golde DW, Clark SC, Wong GG, Gasson JC. Human granulocyte-macrophage colony-stimulating factor is a neutrophil activator. Nature 1985; 314: 361-363.
4. Metcalf D. Molecular control of granulocyte and macrophage production. Prog Clin Biol Res 1985; 191: 323-337.
5. Vasilijic S, Colic M, Vucevic D. Granulocyte-macrophage colony stimulating factor is an anti-apoptotic cytokine for thymic dendritic cells and a significant modulator of their accessory function. Immunol Lett 2003; 86: 99-112.
6. Irons RD, Stillman WS. Cell proliferation and differentiation in chemical leukemogenesis. Stem Cells 1993; 11: 235-242.
7. Le Beau MM, Westbrook CA, Diaz MO, Larson RA, Rowley JD, Gasson JC et al. Evidence for the involvement of GM-CSF and FMS in the deletion (5q) in myeloid disorders. Science 1986; 231: 984-987.
8. Meager A, Wadhwa M, Bird C, Dilger P, Thorpe R, Newsom-Davis J et al Spontaneously occurring neutralizing antibodies against granulocyte-macrophage colony-stimulating factor in patients with autoimmune disease. Immunology 1999; 97: 526-532.
9. Revoltella RP, Laricchia Robbio L, Liberati AM, Reato G, Foa R, Funaro A et al. Antibodies binding granulocyte-macrophage colony stimulating factor produced by cord blood-derived B cell lines immortalized by Epstein-Barr virus in vitro. Cell Immunol 2000; 204: 114-127.
10. Svenson M, Hansen MB, Ross C, Diamant M, Rieneck K, Nielsen H et al Antibody to granulocyte-macrophage colony-stimulating factor is a dominant anti-cytokine activity in human IgG preparations. Blood 1998; 91: 2054-2061.
11. Wadhwa M, Skog AL, Bird C, Ragnhammar P, Lilljefors M, Gaines-Das R et al. Immunogenicity of granulocyte-macrophage colony-stimulating factor (GM-CSF) products in patients undergoing combination therapy with GM-CSF. Clin Cancer Res 1999; 5: 1353-1361.
12. Ullenhag G, Bird C, Ragnhammar P, Frödin JE, Strigård K, Österborg A et al. Incidence of GM-CSF antibodies in cancer patients receiving GM-CSF for immunostimulation. Clin Immunol 2001; 99: 65-74.
13. McNeel DG, Schiffman K, Disis ML. Immunization with recombinant human granulocytermacrophage colony-stimulating factor as a vaccine adjuvant elicits both a cellular and humoral response to recombinant human granulocyte-macrophage colony-stimulating factor. Blood 1999; 93: 2653-2659.
14. Kitamura T, Tanaka N, Watanabe J, Uchida K, Kanegasaki S, Yamada Y et al. Idiopathic pulmonary alveolar proteinosis as an autoimmune disease with neutralizing antibody against granulocyte/macrophage colony-stimulating factor. J Exp Med 1999; 190: 875-880.
15. Uchida K, Nakata K, Trapnell BC, Terakawa T, Hamano E, Mikami A et al High-affinity autoantibodies specifically eliminate granulocyte-macrophage colony-stimulating factor activity in the lungs of patients with idiopathic pulmonary alveolar proteinosis. Blood 2004; 103: 1089-1098.
16. Ragnhammar P, Wadhwa M. Neutralising antibodies to granulocyte-macrophage colony stimulating factor (GM-CSF) in carcinoma patients following GM-CSF combination therapy. Med Oncol 1996; 13: 161-166.
17. Eisenblatter M, Stahl-Hennig C, Kuate S, Stolte N, Jasny E, Hahn H et al. Induction of neutralising antibodies restricts the use of human granulocyte/macrophage colony stimulating factor for vaccine studies in rhesus macaques. Vaccine 2004; 22: 3295-3302.
18. Disis ML, Bernhard H, Shiota FM, Hand SL, Gralow JR, Huseby ES et al Granulocyte-macrophage colony-stimulating factor: An effective adjuvant for protein and peptide-based vaccines. Blood 1996; 88 202-210.
19. Dranoff G. GM-CSF-based cancer vaccines. Immunol Rev 2002; 188 147-154
20. Schiffman K, Disis ML. HER2/neu peptide-based vaccines, with GM-CSF as an adjuvant, in patients with advanced-stage HER2/neu-expressing cancers. Clin Lung Cancer 2000; 2: 74-77.
21. Molldrem J, Dermime S, Parker K, Jiang YZ, Mavroudis D, Hensel N et al. Targeted T-cell therapy for human leukemia: Cytotoxic T lymphocytes specific for a peptide derived from proteinase 3 preferentially lyse human myeloid leukemia cells. Blood 1996; 88: 2450-2457.
22. Molldrem JJ, Lee PP, Wang C, Champlin RE, Davis MM. A PR1-human leukocyte antigen-A2 tetramer can be used to isolate low-frequency cytotoxic T lymphocytes from healthy donors that selectively lyse chronic myelogenous leukemia. Cancer Res 1999; 59: 2675-2681.
23. Kitamura T, Tange T, Terasawa T, Chiba S, Kuwaki T, Miyagawa K et al Establishment and characterization of a unique human cell line that proliferates dependently on GM-CSF, IL-3, or erythropoietin. J Cell Physiol 1989; 140: 323-334.
24. Harris RJ, Pettitt AR, Schmutis C, Sherring PD, Zuzel M, Cawley JC et al. Granuloctye-macrophage colony-stimulating factor as an autocrine survival factor for mature normal and malignant B lymphocytes. J Immunol 2000; 164: 3887-3893.
25. Wadhwa M, Bird C, Fagerberg J, Gaines-Das R, Ragnhammar P, Mellstedt H et al. Production of neutralizing granulocyte-macrophage colony-stimulating factor (GM-CSF) antibodies in carcinoma patients following GM-CSF combination therapy. Clin Exp Immunol 1996; 104: 351-358.
26. Kanakura Y, Cannistra SA, Brown CB, Nakamura M, Seelig GF, Prosise WW et al. identification of functionally distinct domains of human granulocyte-macrophage colony-stimulating factor using monoclonal antibodies. Blood 1991; 77: 1033-1043.
27. Molldrem JJ, Clave E, Jiang YZ, Mavroudis D, Raptis A, Hensel N et al Cytotoxic T lymphocytes specific for a nonpolymorphic proteinase 3 peptide preferentially inhibit chronic myeloid leukemia colony-forming units. Blood 1997; 90: 2529-2534.
28. Wadhwa M, Mellstedt H, Small E, Thorpe R. Immunogenicity of GM-CSF products in cancer patients following immunostimulatory therapy with GM-CSF. Dev Biol (Basel) 2003; 112: 61-67.
29. Vellenga E, Young DC, Wagner K, Wiper D, Ostapovicz D, Griffin JD. The effects of GM-CSF and G-CSF in promoting growth of clonogenic cells in acute myeloblastic leukemia. Blood 1987; 69: 1771-1776.
30. Tanaka N, Watanabe J, Kitamura T, Yamada Y, Kanegasakii S, Nakata K. Lungs of patients with idiopathic pulmonary alveolar proteinosis express a factor which neutralizes granulocyte-macrophage colony stimulating factor. FEBS Lett 1999; 442: 246-250.
31. Uchida K, Beck DC, Yamamoto T, Berclaz PY, Abe S, Staudt MK et al. GM-CSF autoantibodies and neutrophil dysfunction in pulmonary alveolar proteinosis. N Engl J Med 2007; 356: 567-579.
32. Gacouin A, Le Tulzo Y, Suprin E, Briens E, Bernard M, Camus C et al Acute respiratory failure caused by secondary alveolar proteinosis in a patient with acute myeloid leukemia: A case report. Intensive Care Med 1998; 24: 265-267.
33. Birsak CA, van Rossem RN, Nijhuis-Heddes JM, Maartense E. Pulmonary alveolar proteinosis: A complication in patients with hematologic malignancy. Neth J Med 2000; 56: 193-197.
34. Rodriguez-Luaces M, Lafuente A, Martin MP, Mateos P, Ojeda E, Hernandez-Navarro F. Haematopoietic transplantation in pulmonary alveolar proteinosis associated with chronic myelogenous leukaemia. Bone Marrow Transplant 1997; 20: 507-510.
35. Shoji N, Ito Y, Kimura Y, Nishimaki J, Kuriyama Y, Tauchi T et al. Pulmonary alveolar proteinosis as a terminal complication in myelodysplastic syndromes: A report of four cases detected on autopsy. Leuk Res 2002; 26: 591-595.
36. Ohnishi T, Yamada G, Shijubo N, Takagi-Takahashi Y, Itoh T, Takahashi H et al. Secondary pulmonary alveolar proteinosis associated with myelodysplastic syndrome. Intern Med 2003; 42: 187-190.
37. Klein B, Brailly H. Cytokine-binding proteins: Stimulating antagonists. Immunol Today 1995: 16: 216-220.
38. Finkelman FD, Madden KB, Morris SC, Holmes JM, Boiani N, Katona IM et al. Anti-cytokine antibodies as carrier proteins. Prolongation of in vivo effects of exogenous cytokines by injection of cytokine-anti-cytokine antibody complexes. J Immunol 1993; 151 1235-1244.
39. Rusakiewicz S, Molldrem JJ. Immunotherapeutic peptide vaccination with leukemia-associated antigens. Curr Opin Immunol 2006; 18: 599-604.
40. Molldrem JJ, Lee PP, Wang C, Felio K, Kantarjian HM, Champlin RE et al. Evidence that specific T lymphocytes may participate in the elimination of chronic myelogenous leukemia. Nat Med 2000; 6 1018-1023.
41. Elisseeva OA, Oka Y, Tsuboi A, Ogata K, Wu F, Kim EH et al. Humoral immune responses against Wilms tumor gene WT1 product in patients with hematopoietic malignancies. Blood 2002; 99: 3272-3279.
42. Kaufman DC, Baer MR, Gao XZ, Wang ZQ, Preisler HD. Enhanced expression of the granulocyte-macrophage colony stimulating factor gene in acute myelocytic leukemia cells following in vitro blast cell enrichment. Blood 1988; 72: 1329-1332.
43. Bi S, Gao X, Devemy E, Chopra H, Venugopal P, Raza A et al. Cytokine production by in vitro processed and unprocessed haematopoietic cells. Cytokine 2000; 12: 1124-11128.